Research and development of the domestic first self-owned intellectual property rights of diabetes in qinghai a class of new drugs 
 
 

XingShengXiang
 
 
http://www.workercn.cn 
 
 
The 2015-04-14 16:33:42 
 
 
Source: zhonggong network 

    Zhonggong net news (reporter XingShengXiang) recently, qinghai's epicenter of pharmaceutical co., LTD. Academician workstation researchers extracted hypoglycemic lipid-lowering active ingredients of traditional Chinese medicinal herbs radix rehmanniae catalpa, developed China's first self-owned intellectual property rights of the diabetes drug, its hypoglycemic cholesterol-lowering effect is superior to the traditional chemical drugs, and has successfully won the state intellectual property office of China and the United States patent trademark licensing, this new drug is expected to end the situation of our country's diabetes drugs long-term dependence on imports.
 
    Chinese academy of engineering academician liu cx lead tianjin medicine research institute, jilin university state key laboratory of theoretical chemistry and other scientific research units of the researchers in the epicenter in qinghai pharmaceutical co., LTD. Academician workstation in nearly a decade of diabetes drug research and development. At the same time, focusing on key equipment developed, to overcome the industrialization of technology, built the first domestic capacity of 20 tons of radix rehmanniae extract catalpa alcohol production line.
 
    It is reported, the researchers extracted the hypoglycemic lipid-lowering active ingredients in the fresh rehmannia catalpa, and through the individual study found that, catalpa alcohol absorption in the body, quickly, absolute bioavailability of 66.9%, has quick effect, drain quickly and completely, without accumulation in the body, not damaging big organ advantages, in line with the long-term use and interact with other medications without diabetes indications. The study also found, catalpa alcohol for quality control, preparation stability, curative effect, less toxic and side effect of traditional Chinese medicine drugs fall blood sugar, is suitable for the clinical treatment for type 2 diabetes. 
 
    Epicenter of the pharmaceutical industry, general manager zhang ling said, fall blood sugar drug on the market at present temporary ruled by western medicine, with hypoglycemic lipid-lowering, improve insulin resistance mechanisms more features of catalpa alcohol drug market prospects will be very broad. Epicenter of the pharmaceutical industry has completed all preclinical drug research, related enterprise production process through the safety evaluation.
 
    In addition, the epicenter of the pharmaceutical industry also completed in qinghai introduction of radix rehmanniae and adapt to local seed breeding research, and obtained in qinghai province cold cool, under the conditions of strong light cultivated radix rehmanniae catalpa alcohol content than the mainland can increase by about 20%. By qinghai province department of identification, has obtained "qinghai rehmannia no. 1 seed certificate", the guarantee enterprise raw material supply, reduce cost and increase farmers' income will be of great significance.